MQX‐503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: A randomized, controlled trial
Fredrick M. Wigley(Johns Hopkins University), David H. Collier(Amgen (United States)), Janet Pope(St Joseph's Health Care), Maureen D. Mayes(The University of Texas Health Science Center), Richard W. Martin(Grand Rapids Community College), Lee Shapiro(Albany Medical Center Hospital), Sangeeta Sule(Johns Hopkins University), Mary Ellen Csuka(Medical College of Wisconsin), Bashar Kahaleh(University of Toledo), Jeffrey Gregory(Io Therapeutics (United States)), David Fiorentino(Stanford University), Virginia Steen(Georgetown University), Vivien Hsu(Rutgers, The State University of New Jersey), Barry L. Gruber(State University of New York), Murray Baron(McGill University), Frederick J. Dechow(Io Therapeutics (United States)), Naomi F. Rothfield(University of Connecticut), Nadera Sweiss(University of Illinois Chicago), Robert W. Simms(Dartmouth–Hitchcock Medical Center), A. Gilbert(Pearl River Community College), Joseph C. Shanahan(Duke University), Edwin Smith(Medical University of South Carolina)
Cited by 110
Related Papers
The 1982 revised criteria for the classification of systemic lupus erythematosus
|Arthritis & Rheumatism|1982|14.6k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
|New England Journal of Medicine|2000|1.8k
Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI.
|Proceedings of the National Academy of Sciences|1991|752